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Background: Patients with persistent symptoms and/or villous atrophy despite strict adherence to a gluten-free
diet (GFD) have non-responsive celiac disease (NRCD). A subset of these patients has refractory celiac disease (RCD),
yet some NRCD patients may simply be reacting to gluten cross-contamination. Here we describe the effects of a
3-6 month diet of whole, unprocessed foods, termed the Gluten Contamination Elimination Diet (GCED), on NRCD.
We aim to demonstrate that this diet reclassifies the majority of patients thought to have RCD type 1 (RCD1).
Methods: We reviewed the records of all GFD-adherent NRCD patients cared for in our celiac center from 2005-
2011 who were documented to have started the GCED. Response to the GCED was defined as being asymptomatic
after the diet, with normal villous architecture on repeat biopsy, if performed.
Results: Prior to the GCED, all patients were interviewed by an experienced dietitian and no sources of hidden
gluten ingestion were identified. 17 patients completed the GCED; 15 were female (88%). Median age at start of the
GCED was 42 years (range 6-73). Fourteen patients (82%) responded to the GCED. Six patients met criteria for RCD
prior to the GCED; 5 (83%) were asymptomatic after the GCED and no longer meet RCD criteria. Of the 14 patients
who responded to the GCED, 11 (79%) successfully returned to a traditional GFD without resurgence of symptoms.
Conclusions: The GCED may be an effective therapeutic option for GFD-adherent NRCD patients. Response to this
diet identifies a subgroup of patients, previously classified as RCD1, that is not truly refractory to dietary treatment.
Preventing an inaccurate diagnosis of RCD1 avoids immunotherapy. Most patients are able to return to a traditional
GFD without return of symptoms.
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Celiac disease (CD) is an immune-mediated small intestinal
enteropathy triggered by the ingestion of gluten in the
genetically susceptible, with prevalence in the United States
of nearly 1% [1]. While this inflammatory disease mani-
fests classically with GI symptoms, including diarrhea,
malabsorption and weight loss, more commonly patients are
asymptomatic or present with extraintestinal manifestations* Correspondence: jhollon1@jhmi.edu
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reproduction in any medium, provided the orto include iron-deficiency anemia, osteoporosis, migraines,
depression and autoimmune disease comorbidities [2,3]. The
cornerstone of treatment for CD is the gluten free diet
(GFD), with the vast majority of patients demonstrating
substantial clinical improvement within the first few weeks
to months after diet initiation [4,5]. However, there is a
subset of patients who have so-called non-responsive celiac
disease (NRCD) in that they either fail to ever respond to the
GFD or have a recurrence/relapse of symptoms despite being
on a GFD [6].
By far the most common cause of non-response is
failure to adhere to the prescribed GFD, either voluntarily
or unintentionally, thus highlighting the importance of aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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persistently symptomatic patients may be suffering from
co-morbidities such as inflammatory bowel disease or
microscopic colitis rather than active celiac disease [6].
However, a portion of the symptomatic NRCD patient
population are truly on a strict GFD and, of particular
concern, those with villous atrophy on repeat small
intestinal biopsy meet the definition of refractory sprue/
refractory celiac disease (RCD) [6,9-11]. Based on the
immunophenotype of the intraepithelial lymphocytes
(IEL) population, RCD may be further divided into type 1
and type 2; RCD1 demonstrates a normal polyclonal IEL
population, whereas RCD2 is defined by the presence of
aberrant monoclonal IELs [9,12]. Although RCD1 patients
are at increased risk of celiac-associated complications
such as growth retardation and osteoporosis [13],
prognostically, RCD 1 follows a much more benign and
indolent course than RCD2. In contrast to the 5 year
survival rate approaching 100% in RCD1, the more
aggressive RCD2 carries a higher risk of developing
enteropathy-associated T-cell lymphoma (ETCL), and
overall leads to a shortened life expectancy [9,10,14-17],
with a 5 year mortality estimated between 50-60% [14,16].
Corticosteroids are typically first-line therapy for both
RCD1 and RCD2, yet the risk remains that a subset of
RCD1 patients, despite strictly adhering to a proper GFD,
are simply reacting to trace amounts of gluten; below the
20 parts per million (ppm) threshold considered safe for
the vast majority of CD patients.
The University of Maryland Center for Celiac Research
in Baltimore, MD is a tertiary referral center for celiac
disease and gluten-related disorders. As a celiac specialty
clinic, many persistently symptomatic celiac patients are
referred to our center for further evaluation and
management of presumed RCD. Our initial evaluation of
an NRCD patient begins with a comprehensive assessment
of adherence to the diet by an expert dietitian, with focus
not only on intentional noncompliance but also on
determining the patient’s awareness regarding hidden
sources of gluten to include communion wafers, med-
ications and additives [9,18,19]. Whereas treatment for
the non-adherent patient is relatively straight-forward,
difficulty arises when faced with the NRCD patient who
has evidence of persistent disease but no identifiable
source of continued gluten ingestion. Typically, such
patients have already sought out second/third opinions,
have had their diet scrutinized by multiple dietitians and
may have initiated steroid treatment for presumed RCD.
Nevertheless, despite following a strict GFD, there is a
possibility that these patients are still being exposed to,
and are sensitive to, a degree of gluten typically tolerated
by the vast majority of CD patients. In 2005, as a first step
for the management of such NRCD cases, we began to
prescribe a modified diet that aims to eliminate anypossible sources of gluten cross-contamination in an
already strict GFD. If successful, this diet, referred to as
the Gluten Contamination Elimination Diet (GCED),
would not only result in symptom resolution, but would
avoid the inaccurate diagnosis of RCD and, thus, avoid the
expense and adverse health effects of steroid therapy or
other immunomodulators. The aim of this single-center
retrospective chart review is to evaluate and present our
7-year experience of using the GCED to treat NRCD
patients that have failed a well-documented strict GFD.
Methods
This study was approved by the Institutional Review Board
of the University of Maryland, Baltimore (IRB), and was
conducted in accordance with the ethical standards and
regulatory requirements of the IRB. We define NRCD as
biopsy-proven CD with persistence or relapse of symptoms
and/or villous atrophy despite being on a gluten free diet
for ≥12 months. Prior to being considered for the GCED,
dietary compliance was assessed by an experienced dietitian
with expertise in celiac disease; patients must have been
strictly adherent to the GFD, with no identifiable source
of continued gluten exposure. Histological changes on
duodenal biopsies were staged according to the Marsh
Oberhuber classification [20]. RCD is defined as persistent
or relapse of symptoms and villous atrophy (Marsh 3),
despite a strict GFD for ≥12 months. If IEL immu-
nophenotyping was performed on biopsy specimens, either
by CD3/CD8 immunostaining or by T-cell receptor gene
rearrangement analysis by polymerase chain reaction
(PCR), RCD is further subdivided into RCD1 or RCD2
depending on the absence or presence, respectively, of a
monoclonal IEL population. Celiac serology (IgA antibodies
to tissue transglutaminase (tTG) and/or anti-endomysial
antibodies (EMA)) is defined as negative, weak positive or
high using the cut-offs provided by the ELISA kit
manufacturer. Response to the GCED is defined as being
asymptomatic after the diet, with normal villous archi-
tecture (Marsh 0-2) on repeat biopsy, if performed.
Although celiac serology is drawn prior to initiation of the
GCED and upon follow-up, the presence or absence of
celiac auto-antibodies is not used in the definition for
NRCD or RCD, nor is normalization of celiac serology, if
applicable, used as a criterion for response to the GCED.
The GCED, as shown in Table 1, allows: brown and
white rice; all fresh (no frozen, canned or dried) fruits,
vegetables and herbs; fresh meats, poultry, fish and other
non-processed protein sources. Unflavored, unseasoned
dairy products are introduced on week 4. Allowed
condiments are oils, vinegar (excluding flavored and
malt vinegars), honey and salt. Allowed beverages are
100% fruit/vegetable juices, Gatorade, milk, water, and
gluten-free supplemental formulas such as Boost and
Ensure. All cereal grains aside from rice are prohibited.
Table 1 Products allowed/disallowed in the Gluten Contamination Elimination Diet (GCED), targeting the elimination
of gluten cross-contamination
Allowed Not allowed
Grains Plain, unflavored, brown and white rice Millet, sorghum, buckwheat or other inherently
gluten-free grains, seeds, or flours
Fruits/Vegetables All fresh fruits/vegetables Frozen, canned or dried
Proteins Fresh meats Lunch meats
Fresh fish Ham, bacon
Eggs Other processed, self-basted or cured meat products
Dried beans
Unseasoned nuts in the shell
Dairy Butter, yogurt (unflavored), milk (unflavored), aged cheeses Seasoned or flavored dairy products
Processed cheeses
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processed, self-basted or cured meat products are not
allowed. Lastly, a gluten-free multivitamin/mineral daily
supplement is recommended and prescription medication
(verified as gluten-free) is continued. Patients are provided
with sample menus and are asked to keep a food record.
As an aid for compliance, contact information for the
dietitian is provided and patients are encouraged to
update the dietitian frequently on their progress and to
ask questions as they arise. They are instructed to return
to clinic in 3 months for repeat celiac serology labwork
and symptom re-evaluation.
We reviewed the charts of all patients cared for in our
center from 2005 through 2011 who were instructed on the
GCED and met above criteria for NRCD patients on a
well-documented strict GFD. The list of patients receiving
dietary instruction was drawn from the celiac dietitian
database. Patients who did not follow-up in clinic or
otherwise communicate with our clinic after diet education
were excluded as data were unavailable, to include whether
or not the diet was initiated. Compliance was determined
by patient report and dietitian interview; declaration of
stopping the diet before the prescribed minimum of 3 -
months is considered noncompliance.
Results
Of the 1,288 patients with CD seen by our center from
2005 to 2011, a total of 29 (2.3%) patients were instructed
on the GCED and met criteria for diet-adherent NRCD.
Eight of these had no further communication with our
clinic (lost to follow-up). The remaining 21 patients were
documented to have started the GCED, with 4 of themadmitting to cessation of the GCED and return to a
traditional GFD prior to 3 months (noncompliant). Of the
17 compliant patients, 15 were female (88%). The median
age of this group at initial diagnosis of CD was 30 years
(range 1.6 - 52). Median age at initiation of the GCED was
42 years (range 6 – 73); 5 patients were <21 years of age. 14
(82%) patients had primary NRCD, with no improvement
since starting the GFD, on average, 3 years prior to the
GCED (range 1.1 - 4.6). 3 (18%) had secondary NRCD, with
previous remission of disease but subsequent relapse, on
average, 2 years prior to the GCED (range 1 – 3). Prior to
starting the GCED, all but one patient (94%) were
symptomatic, with the asymptomatic patient initiating the
GCED due to high serology and persistent villous atrophy.
Of the symptomatic, the most common symptoms were
diarrhea (50%), followed by fatigue (31%) and abdominal
pain (31%). The demographic details and clinical symptoms
are shown in Table 2.
Response rate of the GCED was 82%, with 14 of the
17 compliant patients responding to the diet. Results of
the GCED in terms of symptom resolution, histology
and celiac serology are discussed below. Table 3 presents
these categories, per patient, pre and post-GCED. Table 4
presents a summary comparison.
Symptom resolution
Prior to starting the GCED, 16 of the 17 compliant
patients (94%) were symptomatic and all but 3 patients
became asymptomatic during the GCED, giving a
symptom response rate of 81% (13/16). Six patients met
the criteria for RCD prior to initiation of the GCED, with
persistent symptoms and Marsh 3 histology. Five out of
Table 2 Demographics and distribution of symptoms of




Pediatric (<21) 5 (29%)
Median age at diagnosis of CD (range) 30 years (1.6 - 52)
Median age at start of GCED (range) 42 years (6 – 73)
Primary non-responsive 14 (82%)
Mean years since start of GFD (range) 3 years (1.1 - 4.6)
Secondary non-responsive/relapsed 3 (18%)





Abdominal pain 5 (31%)
Bloating 3 (19%)
Constipation 2 (12.5%)
Inadequate weight gain 2 (12.5%)
Weight loss 1 (6.2%)
Persistent hypertransaminasemia 1 (6.2%)
Anxiety 1 (6.2%)
Multiple symptoms 9 (56.2%)
CD, celiac disease; GFD, gluten-free diet.
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the GCED and no longer meet criteria for RCD.
Histology
All patients had villous atrophy (Marsh 3) on histology
at the time of their initial CD diagnosis. Twelve of the
17 compliant patients (71%) had repeat duodenal
biopsies taken before initiation of the GCED. Seven
patients demonstrated Marsh 3a/b histology 2.5 months,
on average, prior to the GCED (range 0 – 5). Of these,
patients 5 and 9 demonstrated complete mucosal healing
on repeat endoscopy 5-6 months after starting the
GCED; patient 15 had a normal follow-up video capsule
endoscopy. Patient 17 did not respond symptomatically;
follow-up video capsule endoscopy demonstrated villous
atrophy and the patient was started on corticosteroids
for RCD. Two patients demonstrated Marsh 2 histology
<1 month prior to the GCED; patient 11 was re-biopsied
1 month after the GCED and demonstrated normal
(Marsh 0) histology. Three patients demonstrated Marsh
0–1 histology prior to the GCED. There were two
patients without pre-GCED biopsies that underwent
endoscopy after completion of the GCED; patient 7 had
responded to the diet symptomatically and demonstrated
histologic remission (Marsh 1); patient 10 did notrespond symptomatically to the diet and had persistent
villous atrophy on histology, with IEL polyclonality,
prompting corticosteroid treatment for RCD1.Celiac serology
All patients had elevated tTG celiac serology at ini-
tial histologically-proven CD diagnosis. All compliant
patients had celiac serology drawn prior to the GCED
(average <2 months prior) and after initiation of the
GCED (average <6 months). In all but one patient, tTG
IgA was followed; EMA IgA was followed in a patient
with type 1 diabetes since false positive tTG titers have
been reported in subjects affected by type 1 diabetes
[21]. Thirteen (76%) patients had positive celiac serology
prior to starting the GCED; 10 patients (59%) were
classified as high and the remaining 3 patients (18%)
were in the weak positive range. Of the 10 patients with
high serology, 8 (80%) converted to either negative
serology (40%) or weak positive serology (40%) after the
GCED. This differentiation between negative or weak
positive conversion appeared to make no clinical or
histological difference in outcome; all 8 patients
responded to the GCED. Of the two patients who did not
show improvement in serology, patient 9 had full symptom
resolution and, on endoscopic reassessment, demonstrated
complete mucosal healing. As such, despite the persistent
elevated tTG IgA, this patient responded to the GCED as
well, giving a response rate within the high serology
category of 90%. Two of the 3 weak positive serology
patients responded to the GCED and normalized their
serology, and 3 of the 4 negative serology patients
responded to the GCED, giving a response rate in these
categories of 67% and 75% respectively.Return to traditional GFD
Of the 14 patients who responded to the diet, 11 (79%)
successfully returned to their previous traditional GFD
without resurgence of symptoms or elevated serology.
The mean duration of the GCED among this group was
4.3 months (range 3 – 6 months) and mean duration of
documented follow-up after initiation of the GCED was
20 months (range 1 – 62 months). Of the remaining 3
patients, patient 3 has had recurrence of his symptoms
(diarrhea, fatigue) after attempting to return to a
traditional GFD on at least 3 separate occasions and has
elected to stay on the GCED indefinitely. Patient 6 is
currently back on the GCED due to a recurrence of
hypertransaminasemia and high celiac serology after
returning to the traditional GFD. Patient 16 has been
lost to follow-up and it is unknown whether or not the
patient was able to successfully transition to a normal
diet.






Symptoms before Symptoms after Biopsy before Biopsy after
1 High Neg Abdominal pain None
2 High Neg Inadequate weight gain None
3 High Neg Diarrhea, fatigue None Marsh 3a (RCD) Refused
4 High Neg Constipation None Marsh 3 (RCD)
5 High Weak Pos None None Marsh 3a Marsh 1
6 High Weak Pos Elevated transaminases None Marsh 2
7 High Weak Pos Constipation, fatigue None Marsh 1
8 High Weak Pos Diarrhea None Marsh 1
9 High High Diarrhea, abdominal
pain, bloating
None Marsh 3a (RCD) Marsh 1
10 High High Fatigue, anxiety Fatigue, anxiety Marsh 3a (RCD1)
11 Weak Pos Neg Diarrhea, abdominal pain None Marsh 2 Marsh 0
12 Weak Pos Neg Diarrhea None Marsh 1
13 Weak Pos Weak Pos Inadequate weight gain Inadequate weight gain
14 Neg Neg Diarrhea, bloating, fatigue None Marsh 0
15 Neg Neg Abdominal pain, fatigue None Marsh 3a (RCD), VCE: Atrophy VCE : normal
16 Neg Neg Diarrhea, weight loss None Marsh 3b (RCD) Lost to follow-up




Marsh 3a (RCD) VCE : atrophy
1 Celiac serology defined as negative, weak positive or high using the cut-offs provided by the ELISA kit manufacturer. Tissue transglutaminase (tTG) IgA was
followed in 16/17 patients; anti-endomysial (EMA) IgA was followed in the remaining patient.
Pos, positive; RCD, refractory celiac disease; RCD1, refractory celiac disease type 1; VCE, video capsule endoscopy.
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Four patients had documented initiation of the GCED
but admitted to stopping the diet prior to the initial 3 -
month prescription. Three (75%) of these patients
started the GCED solely for symptoms; they wereTable 4 Presence of symptoms, classification of celiac
serology and Marsh grading of biopsy histology before and
after treatment with Gluten Contamination Elimination Diet
Symptoms Pre-Diet: n (%) Post-Diet: n (%)
Asymptomatic 1 (6%) 14 (82%)
Symptomatic 16 (94%) 3 (18%)
Histology Pre-Diet: n (%) Post-Diet: n (%)
Biopsy obtained 12 (71%) 5 (29%)
Marsh 3 7 1
Marsh 2 2
Marsh 0-1 3 4
Celiac Serology1 Pre-Diet: n (%) Post-Diet: n (%)
High celiac serology 10 (59%) 2 (12%)
Weak positive celiac serology 3 (18%) 5 (30%)
Negative celiac serology 4 (24%) 10 (59%)
1 Celiac serology defined as negative, weak positive or high using the cut-offs
provided by the ELISA kit manufacturer. Tissue transglutaminase (tTG) IgA was
followed in 16/17 patients; anti-endomysial (EMA) IgA was followed in the
remaining patient.serology negative and previously demonstrated Marsh 0-
1 histology on biopsy. One patient stopped the diet after
1.5 months due to complete resolution of diarrhea and
bloating, with no resurgence of symptoms at 7-month
follow-up. The other 2 patients stopped the diet 1.5-
2.25 months after initiation due to no improvement in
their symptoms (diarrhea in one, fatigue/depression in
the other). Normal-appearing mucosa was re-confirmed
in both patients, one by push endoscopy (Marsh 0) and
the other by video capsule endoscopy (normal). The last
patient was started on the GCED for high serology,
symptoms of inadequate weight gain and Marsh 3b
histology 1 month prior to initiation of the diet. The
patient discontinued the diet after 3 weeks, feeling it was
too restrictive, and continues to have symptoms and
elevated serology.Discussion
Our study describes the effects of a 3- 6 month diet of
exclusively whole, unprocessed foods on clinical
symptoms, mucosal pathology and celiac serology in
patients with NRCD that were already properly following
a strict GFD, as assessed by experienced dietitians with
expertise in celiac disease. With the belief that the
majority of such patients are continuing to react to
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goal of this diet is to eliminate exposure to any possible
source of gluten cross-contamination from packaged/
processed foods, to include those labeled gluten-free. In
this study, 82% of our study patients responded to the
GCED, with resolution of symptoms and, when
applicable, resolution of their prior celiac enteropathy.
Most importantly, of the 6 study patients who met
criteria for RCD prior to initiating the GCED, 5 (83%)
responded to the diet; they did not, indeed, have RCD.
The GCED is not an attempt to enforce dietary
adherence on a patient with detected persistent gluten
ingestion, rather it modifies an already strict GFD to
remove the possibility of trace gluten cross-contamination.
Most CD patients can safely tolerate approximately 10 mg
gluten cross-contamination daily, or 500 grams of food
containing 20 ppm of gluten. However, there is a tre-
mendous degree of variability within this population and
some patients may have worsening histological changes
with very low daily gluten exposure [22-24]. The only grains
permitted in the GCED are brown and white rice as even
inherently gluten-free cereal grains have been found to be
significantly cross-contaminated with gluten, presumably
via comingling at harvest, transport and/or milling/
processing. For example, in a recent study that tested 22
single-ingredient inherently gluten-free grains, seeds and
flours, 32% of these products contained >20 ppm gluten;
one product contained 2,925 ppm of gluten [25]. Such a
degree of cross-contamination illustrates how a significant
amount of gluten may be ingested despite no apparent
dietary indiscretions. Interestingly, the fact that the
majority of the patients in our study were subsequently
able to return to their previous strict GFD suggests that
there is a degree of recovery that, once established,
shifts these patients back to a more typical threshold of
gluten reactivity.
There are a number of recent articles discussing the
evaluation of NRCD, with a focus on the approach to finding
other underlying etiologies, such as inadvertent gluten
ingestion or microscopic colitis, that may explain persistent
symptoms [6,26,27]. It was not the intention of this study to
duplicate this topic; rather we aimed to demonstrate that a
number of GFD-adherent NRCD patients who are classified
as RCD1 may not actually be refractory to dietary therapy.
We propose a diagnostic algorithm (Figure 1) that would
avoid misclassification of non-refractory patients, prevent
unwarranted immunomodulatory therapy and preclude
further unnecessary and often costly testing and imaging
modalities employed in the search for non-CD etiologies.
Most of the patients referred to our celiac center for
persistent symptoms, elevated serology, or enteropathy have
unintentional dietary gluten secondary to a lack of proper
dietary education. Therefore, our initial investigation begins
with a comprehensive interview and evaluation by anexperienced dietitian; only those patients without an apparent
source of continued gluten exposure undergo further medical
evaluation and consideration for the GCED.
After ensuring dietary compliance, the primary focus
of an NRCD evaluation should be to rule-out the
presence of RCD2, as this tends to follow an aggressive
clinical course, with a high mortality rate primarily due
to the development of intestinal lymphoma. Early
recognition of RCD2 allows timely and more aggressive
therapy, and encourages the use of diagnostic modalities
such as video capsule endoscopy and CT enterography
in order to exclude malignancy [15]. We recommend
repeat EGD with biopsies as the first investigation in
GFD-adherent NRCD patients to differentiate those with
celiac enteropathy, and therefore possibly RCD, from
those without persistent mucosal disease. Patients with
villous atrophy (i.e. Marsh 3 histology) should undergo
immunophenotyping of the intraepithelial lymphocyte
population by CD3/CD8 immunostaining or T-cell
receptor clonal rearrangement analysis by PCR. Whereas
a monoclonal population equates to RCD2, the presence
of a polyclonal IEL population should not equate to
RCD1 without first a trial of the GCED. Only those
patients who do not symptomatically and histologically
respond to the diet should be diagnosed with RCD1 and
treated appropriately [16,28].
Persistent positive tTG IgA serology cannot be used to
differentiate RCD from those without sustained mucosal
damage, nor can it be used to differentiate RCD subtypes
[16]. Furthermore, studies have shown that normalization of
tTG serology does not necessarily correlate with healed
mucosa [29,30]. These reasons highlight the importance of
endoscopy in the evaluation of NRCD patients. Nonetheless,
tTG is a useful marker for dietary gluten contamination
[31-33]. Our highest response rate was seen in that subset of
patients with high celiac serology, with only 1 patient not
responding to the GCED and, ultimately, being diagnosed
with RCD1. The significance of a weak positive serology is
less clear, and other studies of the NRCD population have
also found little correlation between low titer positivity and
underlying etiology [26]. In our study, there was no
difference between those patients who transitioned from
high to weak positive serology and those patients who went
from high to negative serology.
As Marsh 2 histology has, by definition, normal villi,
we do not include this classification among those
patients with potential RCD, despite the persistence of
pathologic features. However, in those symptomatic CD
patients with elevated serology, neither do we consider
Marsh 2 lesions to be indicative of disease remission. 2
patients in this study had Marsh 2 histology prior to the
GCED; both improved serologically and symptomatically
and one underwent repeat biopsy with subsequent
normal (Marsh 0) histology. For this reason we
Figure 1 Proposed diagnostic algorithm for non-responsive celiac disease. 1. Dietary compliance should be assessed by an experienced
dietitian to rule-out continued gluten exposure. 2. Consider colonoscopy with biopsies if symptoms clinically warrant. 3. To include testing for
pancreatic insufficiency, small bowel bacterial overgrowth, lactose intolerance (based on clinical symptoms). EGD, esophagogastroduodenoscopy;
RCD, refractory celiac disease; RCD1, refractory celiac disease type 1; RCD, refractory celiac disease type 2; GFD, gluten-free diet.
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undergo the GCED prior to any further work-up/
evaluation. Our study also included two symptomatic
patients with positive celiac serology yet Marsh 1 histology
prior to initiation of the GCED; both of whom had
subsequent resolution of symptoms and improved serology.
Marsh 1 lesions would be consistent with disease remission,
suggesting that these patients’ diarrheal symptoms were
secondary to irritable bowel syndrome (IBS) or an underlying
etiology other than gluten contamination. However, while we
recognize that any diet modification carries with it some
degree of placebo effect, the correlation of symptom
improvement with a change in celiac serology is intriguing
and the fact that both patients were subsequently able to
return to their traditional GFD further argues for a non-
placebo response. It should also be noted that one patient’s
endoscopic report documented visualization of signs of
villous atrophy. This raises the possibility of patchy villousrecovery and subsequent missed villous lesions by biopsy
[34,35]. Given this response, we believe that a trial of the
GCED should be considered in a symptomatic NRCD
patient with positive celiac serology, despite apparently
healthy villi.
Eighty-eight percent of our patients in this retrospective
study were female. Although, as with other autoimmune
diseases, there is a female predominance in CD, we were
surprised that only 2 men were treated with the GCED
since its development in 2005. As this study evaluated
only those patients with NRCD who were treated with the
GCED, we should not assume that this represents the
entirety of our GFD-diet adherent NRCD population.
However a previous study, after discounting those patients
with inadvertent gluten ingestion, had an 81% female
predominance in their NRCD population, supporting just
such an assumption [27]. Likewise, a study evaluating
duodenal recovery in CD patients found that male gender
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histology, with females comprising 77% of the study
population but 85% of their nonresponsive category [29].
Owing to the retrospective study design, a major
limitation of our study is the absence of repeat biopsies in
some of our study patients, with 5 patients not undergoing
endoscopy prior to the GCED and only 5 patients being
biopsied after completing the GCED. Whereas the
definition of RCD mandates persistent symptoms and,
thus, an asymptomatic patient would no longer meet
criteria for RCD, documentation of mucosal healing in
those patients who responded clinically and serologically
would strengthen the study results. Moreover, a disease-
specific celiac symptom index would have aided in reliably
assessing symptom resolution. Although compliance with
the GCED was assessed by dietitian interview, we must
consider the reality that strictly adhering to such a limited
diet is difficult and likely more costly than a standard
strict GFD given the focus on fresh, non-processed foods;
these factors may affect adherence disclosure. Our study is
also limited by lack of information on NRCD patients that
were not started on the GCED, and we must recognize
the possibility of a selection bias toward expected
response to the GCED among our study subjects.
Additionally, 8 patients who met NRCD criteria and were
instructed on the GCED by our nutritionist never
followed-up with our clinic and were therefore not
included in our study. As it is our dietitian’s experience
that GCED patients typically contact her periodically for
clarification on diet, these patients likely did not start the
diet. However, some of these patients may have complied
with the diet and simply followed-up with their primary
GI physician; as such, we may be missing useful data.
Lastly, as it was our decision to include all NRCD patients
who initiated the GCED, symptomatic patients with both
negative serology and healed mucosa were not excluded;
75% of the noncompliant patients met this description, as
well as one of the compliant patients. These patients
essentially had little evidence to suggest that removal of
trace gluten contamination would significantly affect their
symptoms.
Conclusions
The GCED may be an effective therapeutic option for
NRCD patients that have already failed a well-
documented strict GFD and may aid in differentiating
those patients reacting to trace amounts of gluten
contamination from those who truly have RCD1. By
avoiding an inaccurate diagnosis of RCD1, patients are
able to avoid corticosteroids or immunotherapy. The
expense and potential adverse health effects of this type
of therapy make a dietary solution, aimed at the
underlying etiology, particularly attractive. Moreover, a
successful trial of the GCED in those patients with ahigh likelihood of having gluten cross-contamination,
for instance those with high celiac serology, would avoid
further unnecessary medical work-up. Most patients
who respond to a 3-6 month course of the GCED are
subsequently able to return to a traditional GFD without
return of symptoms. Multi-center studies implementing
the GCED in subjects affected by NRCD despite strict
diet-adherence should be performed to confirm our data
and, if confirmed, to re-evaluate the actual incidence of
RCD1 as it may currently be over-estimated.
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